Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
23/07/2026 13:14
BRIEF-Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors July 23 (Reuters) - Nuvectis Pharma Inc NVCT.O:
CIPROCOPAN (NXP100) RECEIVES MARKETING APPROVAL IN CHINA FOR THE TREATMENT OF PATIENTS WITH PNH PREVIOUSLY UNTREATED WITH COMPLEMENT INHIBITORS
Source text: ID:nGNEbzjFWZ
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin